BP
AGIO icon

Ballentine Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Ballentine Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,709
Closed -$389K – 432
2017
Q2 		$389K Hold
6,709
– – 0.03% 233
2017
Q1 		$392K Sell
6,709
-3,000
-31% -$144K 0.03% 146
2016
Q4 		$405K Buy
+9,709
New +$509K 0.03% 127

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Ballentine Partners's AGIO Position: Q3 2017 in Review

Ballentine Partners sold out of Agios Pharmaceuticals (AGIO) in Q3 2017, closing a stake of 6,709 shares — an estimated $389K sold.

Ballentine Partners first reported a position in AGIO in Q4 2016 and held it in 3 quarters. The position peaked at $405K in Q4 2016. 171 funds tracked by Wall St. Rank hold AGIO as of Q3 2017.

  • Ballentine Partners reported no remaining Agios Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Ballentine Partners sold 6,709 Agios Pharmaceuticals shares in Q3 2017, an estimated $389K.
  • Ballentine Partners first reported a position in Agios Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Ballentine Partners's Agios Pharmaceuticals position peaked at $405K in Q4 2016.
  • 171 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2017.

Based on Ballentine Partners's 13F filing for Q3 2017, filed 6 Nov 2017.